LATEST PSYCHEDELICS STOCKS NEWS

425 views4 min read

Mydecine Welcomes Dr. Victoria Hale as Newest Independent Board Member

Mydecine Innovations Group
VANCOUVER, British Columbia, Feb. 03, 2022 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced the appointment of Dr. Victoria Hale to the company’s Board of Directors. Dr. Hale ... Read More...
1181 views6 min read

Red Light Holland’s Partner CCrest Laboratories Approved By Health Canada to Supply Psilocybin to the Special Access Program

Red Light Holland
Toronto, Ontario--(Newsfile Corp. - January 28, 2022) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of a premium brand of magic truffles, is pleased to congratulate its partner CCrest Lab for being approved... Read More...
Financials1382 views4 min read

MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2022

Mind Cure Health
VANCOUVER, BC, Jan. 25, 2022 - Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology and research for psychedelics, today announced its financial results and operational highlights for the three and six months ended November 30, 2021.  All amounts are stated in Canadian dolla... Read More...
1281 views4 min read

Psyence looks to expand capital market opportunities in the UK and Europe

Psyence Group
TORONTO, Jan. 21, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is exploring capital market opportunities to access a broader pool of United Kingdom (“UK”) and European in... Read More...
476 views9 min read

Allied Corp Signs Supply Agreement for 1000KGS Monthly and Completes Manufacturing Process for Allied Inside™ Veteran Focused CBD Cigarette

Allied
KELOWNA, British Columbia, Jan. 19, 2022 -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce the signing of a dual-purpose agreement with Porter Ventures, LLC that is based in the United States. All products involved with this working relationship are below the 0.3% THC limit and are legal to be sold in the Un... Read More...
372 views4 min read

Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study

Algernon Pharmaceuticals
VANCOUVER, British Columbia, Jan. 19, 2022 -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has filed a combined Clinical Trials of Investigational Medicinal Products and Ethics Approval application,... Read More...
M & A706 views4 min read

Novamind Closes Arizona Acquisition

Novamind
Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.TORONTO, ON / ACCESSWIRE / January 18, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind"), a leading mental health company specialized in psy... Read More...
1512 views5 min read

Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Psychedelics Today

Entheon Biomedical
Expanding brand awareness and access to HaluGen's Psychedelics Genetic Test KitVancouver, British Columbia--(Newsfile Corp. - January 18, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge b... Read More...
117 views8 min read

Red Light Holland to Collaborate with Advocacy Group, Psychedelic Medicine Alliance Washington to Promote Proposed Psilocybin Legalization Bill in Washington State

Red Light Holland
Proposed Senate Bill 5660 would legalize the supported adult use of psilocybin by people 21 years of age and older (4.1m) in Washington StateRed Light Holland hires lobbyist recommended by Psychedelic Medicine Alliance Washington, James ParibelloRed Light Holland to start a Social Media campaign and promote online educational events led b... Read More...
782 views4 min read

Optimi Health Submits Natural Psilocybin Combined Drug Delivery and Extraction Formulations for Provisional Patent

Optimi Health
VANCOUVER, British Columbia, Jan. 18, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to announce a second provisional patent for a propriet... Read More...
1245 views5 min read

Survey Finds Majority of Affected Americans Approve of Psychedelics as an Alternative Treatment to Address Anxiety, Depression and PTSD

Delic Holdings
VANCOUVER, BC, Jan. 18, 2022 - A new survey conducted by The Harris Poll on behalf of Delic Holdings Corp ("Delic") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), a leader in new medicines and treatments for a modern world, reports that nearly two thirds of Americans who suffer from anxiety/depression/PTSD (65%) believe that psy... Read More...
LOI574 views7 min read

Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health Canada’s Special Access Program

Mydecine Innovations Group
VANCOUVER, British Columbia, Jan. 18, 2022 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced it has signed a Letter of Intent (LOI) with The Newly Instit... Read More...
46 views5 min read

Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

Revive Therapeutics
IRB approval to initiate Phase 2 study for methamphetamine abuse disorders Advancing psilocybin oral thin film, microneedle patch and biosynthesis programs TORONTO, Jan. 17, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and ... Read More...
868 views4 min read

Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product

Numinus Wellness
The trial evaluates Numinus' first trademarked product and patent-pending production process VANCOUVER, BC, Jan. 14, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to announce that it has formally submitted the clinical trial application ("CTA") to Health Canada for its... Read More...
Calendar1221 views2 min read

Numinus Announces Cancellation and Rescheduling of Annual General Meeting of Shareholders

Numinus Wellness
VANCOUVER, BC, Jan. 13, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announced today that its annual general meeting of shareholders (the "AGM"), which was originally scheduled to be held on Friday, January 21, 20... Read More...
379 views8 min read

Mydecine to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic-Assisted Psychotherapy For Patients

Mydecine Innovations Group
VANCOUVER, British Columbia, Jan. 13, 2022 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, announced today they would be launching The Special Access Support and Suppl... Read More...
875 views3 min read

Pure Extracts Signs White Label Agreement with West Coast Licensed Producer

Pure Extracts Technologies
VANCOUVER, British Columbia, Jan. 12, 2022 -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, is pleased to announce that its wholly owned subsidiary, Pu... Read More...
41 views4 min read

Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain

Cybin
-Enrollment expected to begin in early 2022 - TORONTO, January 11, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™", today announced that an Institutional Review Board ("IRB") has approved a Company-sponsored feasibility study us... Read More...
635 views4 min read

Delic Corp CEO to Participate in HC Wainwright Bioconnect Virtual Conference January 2022 Investor Conference

Delic Holdings
Matt Stang, Co-founder and CEO of Delic Corp, Will Present the Company's Strategic Outlook During the Conference, Jan 10-13 VANCOUVER, BC, Jan. 10, 2022 - Delic Holdings Corp ("Delic") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced details regarding Matt Stang, co-found... Read More...
875 views4 min read

Mydecine Innovations Group Engages JBN Partners, LLC for Marketing Services

Mydecine Innovations Group
VANCOUVER, British Columbia, Jan. 07, 2022 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced that the company has engaged JBN Partners, LLC (“JBN”) to in... Read More...
856 views6 min read

Cybin Announces Additional Adelia Milestone Achievement

Cybin
TORONTO, January 06, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on psychedelic pharmaceutical therapies, is pleased to announce that Adelia Therapeutics Inc. ("Adelia"), a wholly-controlled subsidiary of Cybin, has achieved the milestone identified as Year ... Read More...
871 views8 min read

Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete Second Evaluation Under a Health Canada Approved cGMP Laboratory

Red Light Holland
Red Light Holland and CCrest Laboratories continue to demonstrate their strong commitment to the highest regulatory Health Canada compliance standards, as the two synergistic companies applaud, and are paying close attention to, Health Canada's updated Special Access Program (SAP)Toronto, Ontario--(Newsfile Corp. - January 6, 2022) - Red ... Read More...
902 views4 min read

Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics
Approximately 700 subjects participated in the enrollment periodExpected to begin subject enrollment in Turkey by mid-FebruaryExpected to complete enrollment in Q1-2022 TORONTO, Jan. 06, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the... Read More...
887 views4 min read

Novamind Unveils New Design Concept for Clinics

Novamind
TORONTO, ON / ACCESSWIRE / January 5, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind"), a leading mental health company specialized in psychedelic medicine, today unveiled its clinic design concept (the "Design Concept") to accommodate the unique requirements of psychedelic-assisted psychotherapy. The Design Concept will l... Read More...
404 views5 min read

Optimi Health Provides Dealer License Update and Comments on Health Canada’s Amendments to the Special Access Program (SAP)

Optimi Health
VANCOUVER, British Columbia, Jan. 05, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to report the successful completion of the Health Cana... Read More...
1561 views4 min read

Field Trip Health Ltd. to Participate in H.C. Wainwright Bioconnect Virtual Conference in January 2022

Field Trip Health
TORONTO, Jan. 05, 2022 -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip’s Co-Founder and CEO, Joseph del Moral, and Chief Scientific Officer, Dr. Nathan Bryson, will participate in a virtual fireside chat a... Read More...
1350 views4 min read

Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference

Bright Minds Biosciences
VANCOUVER, British Columbia, Jan. 04, 2022 -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, and ... Read More...
1308 views4 min read

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics
Screened approximately 700 subjects and expanding to Eastern Europe, including Turkey, as part of its clinical diversification plans to support global regulatory approvalsNo serious adverse events and safety concerns reported to date in the Phase 3 clinical trialExpected to complete enrollment in Q1-2022 TORONTO, Dec. 29, 2021 -- Revive T... Read More...
Financials165 views7 min read

Cybin Provides 2021 Year End Summary

Cybin
TORONTO, December 22, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™" is pleased to provide a year-end summary of its major milestones and key catalysts from 2021 that it believes have positioned the Company for... Read More...
901 views6 min read

Numinus Wellness Commends Health Canada on Special Access Programme Amendments to Restore Potential Access to Psychedelic Medicines

Numinus Wellness
Policy amendment allows practitioners to request access to psychedelic drugs for patients with serious or life-threatening conditions on a case-by-case basis VANCOUVER, BC, Dec. 22, 2021 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI), a leader in psychedelics-focused mental healthcare, commends Health Canada's leadership for amending th... Read More...
185 views4 min read

BetterLife’s Wholly-Owned Subsidiary, Altum Pharmaceuticals, Obtains Non-Dilutive Financing Commitment From Strategic Investor!

BetterLife Pharma
VANCOUVER, British Columbia, Dec. 22, 2021 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU) today announced that its wholly-owned subsidiary, Altum Pharmaceuticals Inc. (“Altum”), has signed an agreement with an European-based investor group to complete a non-brokered financing of up to US$5... Read More...





Make smarter investment strategies
with in-depth news reports

Join our subscribers!